Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed CE marks portable circulatory support system:

This article was originally published in Clinica

Executive Summary

Abiomed has CE marked its portable circulatory support driver for sale in Europe. The portable driver is designed to support Danvers, Massachusetts-based Abiomed's AB5000 ventricular assist device (VAD). It is lightweight, quiet and reliable, and is designed to improve patient care while lowering costs. The AB5000 portable driver provides a greater degree of mobility and improves the quality of life of patients during VAD use to aid myocardial recovery. The AB5000 VAD is already CE-marked in Europe and has supported patients for up to 312 days. Outside of the US, the AB5000 is used as a bridge-to-recovery and bridge-to-transplant (BTT) device, and the portable driver is expected to greatly enhance the company's BTT market opportunity. The circulatory support driver has not yet been approved in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel